3.19
+0.98(+44.34%)
Currency In USD
| Previous Close | 2.21 |
| Open | 3.22 |
| Day High | 4.78 |
| Day Low | 2.47 |
| 52-Week High | 13.52 |
| 52-Week Low | 2.02 |
| Volume | 167.46M |
| Average Volume | 277,913 |
| Market Cap | 16.67M |
| PE | -0.32 |
| EPS | -10.01 |
| Moving Average 50 Days | 2.93 |
| Moving Average 200 Days | 5.48 |
| Change | 0.98 |
If you invested $1000 in Beyond Air, Inc. (XAIR) since IPO date, it would be worth $60.17 as of September 08, 2025 at a share price of $3.55. Whereas If you bought $1000 worth of Beyond Air, Inc. (XAIR) shares 5 years ago, it would be worth $34 as of September 08, 2025 at a share price of $3.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds
GlobeNewswire Inc.
2 hours ago
GARDEN CITY, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve t
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
GlobeNewswire Inc.
10 hours ago
BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and D
Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 03, 2025 12:00 PM GMT
GARDEN CITY, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve t